Share Name |
Share Symbol |
Market |
Type |
Share ISIN |
Share Description |
Advanced Medical Solutions Group Plc |
LSE:AMS |
London |
Ordinary Share |
GB0004536594 |
ORD 5P |
|
Price Change |
% Change |
Share Price |
Bid Price |
Offer Price |
High Price |
Low Price |
Open Price |
Shares Traded |
Last Trade |
|
4.50 |
1.72% |
265.50 |
264.00 |
265.00 |
265.00 |
259.50 |
261.00 |
390,312 |
16:35:02 |
Industry Sector |
Turnover (m) |
Profit (m) |
EPS - Basic |
PE Ratio |
Market Cap (m) |
Health Care Equipment & Services |
86.8 |
10.1 |
4.0 |
66.5 |
572 |
Advanced Medical Solutions Share Discussion Threads

Showing 7351 to 7375 of 7375 messages
Date | Subject | Author | Discuss |
---|
08/4/2021 17:59 | Aiui Rapid Liquiband was expected to get FDA approval in Q1 this year, and that should help, plus of course the very successful vaccination programme in the US which should soon increase elective surgery to normal levels. AMS could prove a tasty morsel for one of the many giant US medical companies. |  dozey3 | |
08/4/2021 13:26 | Since April 5th this is a different company - according to the sp!
;-) |  wetdream | |
07/4/2021 14:18 | AMS are a rock solid Company with a good management team. They are waiting approval from FDA on some next generation products which IMHO will take the share price to a higher level. |  dealit | |
07/4/2021 10:39 | Off the radar |  nickg2 | |
30/3/2021 16:47 | As elective surgery starts to get busier as we come out of lockdown who thinks this company will start its climb back up? |  nickg2 | |
11/3/2021 11:08 | Amazing some of the six-figure trades that suddenly appear in a largely ignored stock.
Presumably just blocks being transferred at an agreed price, as the share price barely moves. |  wetdream | |
11/3/2021 09:51 | If the trading statement is correct steady progress in difficult times. |  dealit | |
11/3/2021 07:55 | Plenty of volume yesterday.
Everything’s looking rosy. |  wetdream | |
22/2/2021 15:26 | Well, it was to someone.
;-) |  wetdream | |
22/2/2021 12:30 | 500k could have been a buy |  cynic1 | |
22/2/2021 10:40 | Always seems to be someone with 500k to sell...
;-) |  wetdream | |
21/2/2021 22:47 | Hi All, an article on the investment case for AMS post half year 2020 results. Available here: hxxps://www.thetwentiestrader.com/post/advanced-medical-solutions-licking-its-wounds |  thetwentiestrader | |
21/2/2021 16:43 | AMS were first tipped in the MoS in 2002. Just wish I'd bought more at 10p. Solid company with good forward thinking management. |  cynic1 | |
21/2/2021 15:35 | Mail on Sunday |  cynic1 | |
21/2/2021 14:37 | Good, but what is the MOS? |  dozey3 | |
21/2/2021 13:40 | AMS one of the top 10 biggest bargain tips in the MOS |  cynic1 | |
09/12/2020 21:53 | dealit,
I have a love/hate relationship with AMS...
I’ve always thought of them as a well-run, if undynamic, company with a solid product range and in a pretty ‘fireproofR17; business sector.
A bit too dependent on acquisitions (that I struggle to appreciate) but hey-ho, ‘steady as she goes’.
But then along came Trump with his ‘America First’ campaign in the middle of the pandemic and AMS just got left behind. Not entirely their fault, but irritating that it’ s set them back as you point out at least 12 months.
They’ve done well to hold on to some quality funds as supporters, so I guess extra patience is required. |  wetdream | |
09/12/2020 15:42 | wetdream-I have posted part of an announcement from earlier in the year and feel that AMS S/P should head north on FDI approval IMHO.----
The LiquiBand® XL critical pilot study has been completed with three different formulations successfully meeting our objective of 14-day wear time. However, some of the variants demonstrated extended set time. The lead formulation, which we believe maximises our potential for long term commercial success on all product features, is an accelerated formulation of LiquiBand® that will require additional stability and biocompatibility data along with a repeat of the clinical study as part of the FDA filing. The additional work required on this lead formulation means that we now expect to file for 510K approval in the first quarter of 2021. We expect the financial impact of this delayed approval to be offset by the stronger than anticipated LiquiBand® market share improvement and short term commercial agreements with US hospitals to encourage additional LiquiBand® adoption in the run up to the LiquiBand® XL approval. Once approved, LiquiBand® XL will allow entry into the market for care of larger wounds and unlock further growth potential in the LiquiBand® business with all partners. |  dealit | |
07/12/2020 09:16 | Good for divis - hence continued institutional support.
Doubt anyone holds for capital growth. Been on the slide for the last couple of years. |  wetdream | |
02/12/2020 18:33 | I've held quite a few here for years, adding the divi's back as shares
I see this doing well in the next few years again- happy to hold thru the doldrums
unloved but a great long-term hold for me |  malcontent | |
02/12/2020 18:26 | Not a high profile sector, I guess.
Always thought of them as a takeover target, but not in these Covid-obsessed times. |  wetdream | |
01/12/2020 22:15 | Really nice jump Not even sure if anyone cares anymore. |  whitebicycle | |
24/11/2020 07:52 | Looks like the news caused some trading algorithms to go into meltdown!
Dozens of single share trades before 8.30am. Weird. |  wetdream | |
23/11/2020 16:32 | The market loved todays acquisition news by AMS. |  dealit | |
23/11/2020 16:31 | Advanced Medical Solutions acquires Raleigh Adhesive Coatings, reports Investor's Champion.
For the 6 months ending 31 October Raleigh generated revenue of £3.9m and operating profit of £0.8m, compared to the prior year’s loss of £0.3m. The £22m acquisition cost therefore represents quite a multiple, suggesting AMS thinks highly of this business. |  energeticbacker | |